321 related articles for article (PubMed ID: 36034485)
1. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
ArXiv; 2023 Jan; ():. PubMed ID: 36034485
[TBL] [Abstract][Full Text] [Related]
2. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
[TBL] [Abstract][Full Text] [Related]
3. Interpretative immune targets and contemporary position for vaccine development against SARS-CoV-2: A systematic review.
Chauhan N; Soni S; Gupta A; Aslam M; Jain U
J Med Virol; 2021 Apr; 93(4):1967-1982. PubMed ID: 33270225
[TBL] [Abstract][Full Text] [Related]
4. Vaccines platforms and COVID-19: what you need to know.
Acosta-Coley I; Cervantes-Ceballos L; Tejeda-Benítez L; Sierra-Márquez L; Cabarcas-Montalvo M; García-Espiñeira M; Coronell-Rodríguez W; Arroyo-Salgado B
Trop Dis Travel Med Vaccines; 2022 Aug; 8(1):20. PubMed ID: 35965345
[TBL] [Abstract][Full Text] [Related]
5. Whole Inactivated Virus and Protein-Based COVID-19 Vaccines.
Hotez PJ; Bottazzi ME
Annu Rev Med; 2022 Jan; 73():55-64. PubMed ID: 34637324
[TBL] [Abstract][Full Text] [Related]
6. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
Amanpour S
Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
[TBL] [Abstract][Full Text] [Related]
7. Classical and Next-Generation Vaccine Platforms to SARS-CoV-2: Biotechnological Strategies and Genomic Variants.
Simões RSQ; Rodríguez-Lázaro D
Int J Environ Res Public Health; 2022 Feb; 19(4):. PubMed ID: 35206580
[TBL] [Abstract][Full Text] [Related]
8. Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19.
Bezbaruah R; Borah P; Kakoti BB; Al-Shar'I NA; Chandrasekaran B; Jaradat DMM; Al-Zeer MA; Abu-Romman S
Front Mol Biosci; 2021; 8():635337. PubMed ID: 33937326
[TBL] [Abstract][Full Text] [Related]
9. Review of COVID-19 Vaccines Approved in the United States of America for Emergency Use.
Vasireddy D; Atluri P; Malayala SV; Vanaparthy R; Mohan G
J Clin Med Res; 2021 Apr; 13(4):204-213. PubMed ID: 34007358
[TBL] [Abstract][Full Text] [Related]
10. RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.
Wong TY; Russ BP; Lee KS; Miller OA; Kang J; Cooper M; Winters MT; Rodriguez-Aponte SA; Dalvie NC; Johnston RS; Rader NA; Wong ZY; Cyphert HA; Martinez I; Shaligram U; Batwal S; Lothe R; Chandrasekaran R; Nagar G; Rajurkar M; Rao H; Bevere JR; Barbier M; Love JC; Damron FH
mSphere; 2022 Aug; 7(4):e0024322. PubMed ID: 35968964
[TBL] [Abstract][Full Text] [Related]
11. Mapping the technological landscape of SARS, MERS, and SARS-CoV-2 vaccines.
Nascimento Júnior JAC; Santos AM; Cavalcante RCM; Quintans-Júnior LJ; Walker CIB; Borges LP; Frank LA; Serafini MR
Drug Dev Ind Pharm; 2021 Apr; 47(4):673-684. PubMed ID: 33826439
[TBL] [Abstract][Full Text] [Related]
12. Exigency of Plant-Based Vaccine against COVID-19 Emergence as Pandemic Preparedness.
Chattopadhyay A; Jailani AAK; Mandal B
Vaccines (Basel); 2023 Aug; 11(8):. PubMed ID: 37631915
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 vaccine development: where are we?
Galdiero M; Galdiero M; Folliero V; Zannella C; De Filippis A; Mali A; Rinaldi L; Franci G
Eur Rev Med Pharmacol Sci; 2021 Mar; 25(6):2752-2784. PubMed ID: 33829462
[TBL] [Abstract][Full Text] [Related]
14. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
15. Viral vector and nucleic acid vaccines against COVID-19: A narrative review.
Khoshnood S; Ghanavati R; Shirani M; Ghahramanpour H; Sholeh M; Shariati A; Sadeghifard N; Heidary M
Front Microbiol; 2022; 13():984536. PubMed ID: 36118203
[TBL] [Abstract][Full Text] [Related]
16. Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population.
Bednarski E; Del Rio Estrada PM; DaSilva J; Boukadida C; Zhang F; Luna-Villalobos YA; Rodríguez-Rangel X; Pitén-Isidro E; Luna-García E; Díaz Rivera D; López-Sánchez DM; Tapia-Trejo D; Soto-Nava M; Astorga-Castañeda M; Martínez-Moreno JO; Urbina-Granados GS; Jiménez-Jacinto JA; Serna Alvarado FJ; Enriquez-López YE; López-Arellano O; Reyes-Teran G; Bieniasz PD; Avila-Rios S; Hatziioannou T
mBio; 2022 Aug; 13(4):e0084022. PubMed ID: 35735743
[TBL] [Abstract][Full Text] [Related]
17. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
[TBL] [Abstract][Full Text] [Related]
18. Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease.
Belete TM
Infect Drug Resist; 2021; 14():151-161. PubMed ID: 33500636
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
20. Environmental Risk Assessment of Recombinant Viral Vector Vaccines against SARS-Cov-2.
Baldo A; Leunda A; Willemarck N; Pauwels K
Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34063733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
